BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q3 EPS of ($0.95), $0.07 worse than the analyst estimate of ($0.88). Revenue for the quarter came in at $120.7 million versus the consensus estimate of $107.62 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.